In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Inhibikase Therapeutics (IKT – Research Report), with a price target of $27.00. The company’s shares opened today at $3.36.
White covers the Healthcare sector, focusing on stocks such as SAB Biotherapeutics, TG Therapeutics, and Inhibikase Therapeutics. According to TipRanks, White has an average return of -12.4% and a 29.64% success rate on recommended stocks.
Inhibikase Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $27.00.
See Insiders’ Hot Stocks on TipRanks >>
IKT market cap is currently $18.94M and has a P/E ratio of -0.88.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inhibikase Therapeutics Inc is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Diseases and related disorders inside and outside the brain. Its pipeline product, IkT-148009, targets underlying disease mechanisms to reverse the course of Parkinson’s disease and the GI complications of Parkinson’s disease.
Read More on IKT:
